BioSim™ anti-Avelumab (Bavencio®) (Human) ELISA Kit
- Usually Shipped in 5 Working Days
- 100 Assays
- Storage Conditions:
- Shipping Conditions:
- Gel Pack
- Shelf life:
- 12 months
Avelumab (Bavencio®) is a fully human anti-PD-L1 IgG1 lambda monoclonal antibody that has a molecular weight of approximately 147 kDa. Avelumab binds PD-L1 and blocks the interaction between PD-L1 and its receptors PD-1 and B7-1. By inhibiting PD-L1 interactions, avelumab is thought to enable the activation of T-cells and the adaptive immune system. By retaining anative Fc-region, avelumab is thought to engage the innate immune system and may induce antibody-dependent cell-mediated cytotoxicity. Importantly, avelumab has not shown antibody-dependent cell mediated cytotoxicity against immune cell subsets in humans. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSim™ anti-Avelumab ELISA kit is designed to detect antibody against Avelumab with high specificity and sensitivity in biological matrices.
Alternate Name: N/A
Tag Line: A Sandwich ELISA kit for the qualitative determination of antibody against Avelumab in human serum or plasma.
Summary: • Detection method- Absorbance (450 nm) • Species reactivity- Human • Application- qualitative determination of antibody against Avelumab (Bavencio) in human serum and plasma
Detection Method: Absorbance (450 nm)
Sample Type: Human serum and plasma
Species Reactivity: Human
Applications: This ELISA kit is used for Qualitative determination of antibody against Avelumab (Bavencio) in serum and plasma
Features & Benefits: Easy, convenient, sensitive and time-saving method toqualitative determination of antibody against Avelumab (Bavencio) in human serum and plasma. Cross Reactivity: Avelumab (Bavencio®) infusion camouflages/masks the presence of antibody to Avelumab in serum/plasma samples. Therefore, blood sampling time is critical for detection of antibody to Avelumab. It is convenient to obtain blood sample just before the infusion or at least 2 weeks after the infusion of Pembrolizumab.